Composite Peptide Vaccines
Targeting broad strain coverage and long-lasting protection.
Lead Candidate
LHNVD-105 is adjuvanted, universal (broadly reactive) influenza vaccine, built on a composite peptide platform.
Our Patented Composite Peptide Technology allows conserved antigens from other viruses and bacteria to be quickly added.
To ensure maximum coverage of different influenza strains, we have identified and validated conserved peptides from three key components of the influenza virus: the hemagglutinin, the neuraminidase, and matrix protein combined with a T-cell epitope to generate neutralizing antibodies and a balanced cytokine response. In doing so, our universal influenza vaccine can provide multiple pathways to respond to different strains, making it harder for these strains to escape the scope of the vaccine.
Partner
Collaborating with the world’s most experienced adjuvant group.
The Covid-19 pandemic has shown the biotechnology and pharmaceutical industries that rapidly developed vaccines require a high standard of efficacy, scalability, adaptability, affordability, and minimal logistics to ensure widespread use.
That’s why Longhorn is working with one of the world’s most experienced adjuvant group, the Walter Reed Army Institute of Research, to develop a universal influenza vaccine (LHNVD-105) with a low dose requirement and alternative routes of administration (e.g., intranasal/intradermal). This would eliminate the need for needles, making administration more accessible than other influenza vaccines in the developing world.
Through our Covid-19 and universal influenza vaccine programs, amongst other pathogen testing and vaccine tools under development, we will continue to innovate and expand our solution set.
Research
Pre-clinical studies suggest that LHNVD-105 provides broader coverage than current seasonal vaccines and is more cost-effective.
To ensure maximum coverage of different influenza strains, we have identified and validated conserved peptides from three key components of the influenza virus, in turn making it harder for these strains to escape the scope of the vaccine.
